Shot For Pollen Allergy: SCIT Evidence, Extracts, and What to Expect
Yes — there is a shot for pollen allergy: subcutaneous immunotherapy (SCIT) formulated with the patient's specific pollen sensitizations. Cochrane Calderón 2007 found symptom SMD −0.73 across 51 RCTs in predominantly grass-pollen patients. Durham 1999 NEJM showed 3-4 year grass SCIT produced remission lasting 3+ years post-treatment. Formulation is patient-specific — no universal pollen shot exists.
7 peer-reviewed sources
The shot for pollen allergy is subcutaneous immunotherapy (SCIT) — a 3-to-5-year course of injected pollen extracts matched to the patient's specific IgE sensitization. Cochrane SMD −0.73 for seasonal AR; Durham 1999 NEJM showed 3+ year post-treatment remission.
The essentials
Yes — there is a shot for pollen allergy. It is subcutaneous immunotherapy (SCIT) formulated with extracts of the specific pollen species the patient is IgE-sensitized to, confirmed by skin prick testing or serum-specific IgE testing. SCIT is administered weekly during a 24-28-week build-up phase, then every 2-4 weeks during a 3-5 year maintenance phase (Cox L et al., J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55, DOI 10.1016/j.jaci.2010.09.034).
Pollen SCIT has the strongest evidence base of any allergen category outside of Hymenoptera venom. The Cochrane seasonal allergic rhinitis meta-analysis (Calderón MA et al., Cochrane 2007;CD001936, DOI 10.1002/14651858.CD001936.pub2) analyzed 51 RCTs involving 2,871 patients — predominantly grass-pollen-sensitized — and found symptom SMD of −0.73 (95% CI −0.97 to −0.50) and medication-use SMD of −0.57 (95% CI −0.82 to −0.33) for SCIT versus placebo. Adrenaline was used in 0.13% of active-treatment injections in that dataset, with no fatalities.
The landmark durability evidence is pollen-specific: Durham SR et al. (NEJM 1999;341:468-475, DOI 10.1056/NEJM199908123410702) showed that patients who completed 3-4 years of grass SCIT and then stopped maintained clinical remission for at least 3 further years post-discontinuation with persistent immunologic changes. Walker SM et al. (JACI 2001;107:87-93, DOI 10.1067/mai.2001.112027) reported approximately 49% reduction in hay-fever symptoms versus 15% placebo and approximately 80% reduction in medication score versus 18% placebo.
Curex pairs at-home IgE testing with board-certified allergist review to identify which specific pollen species — grass, ragweed, tree, weed — are driving a patient's seasonal symptoms before any immunotherapy formulation is prescribed.
FDA-standardized pollen extracts available in the US include: short ragweed (Ambrosia artemisiifolia), Bermuda grass (Cynodon dactylon), Kentucky bluegrass (Poa pratensis), perennial rye (Lolium perenne), redtop (Agrostis gigantea), sweet vernal (Anthoxanthum odoratum), and timothy (Phleum pratense). These standardized extracts have defined potency in biological allergy units (BAU) per mL. Tree pollens (birch, oak, maple, cedar) and weed pollens beyond ragweed are largely non-standardized — extract potency varies by manufacturer. Mountain cedar SCIT and most mold species outside Alternaria are under-studied, and honest data gaps should be disclosed to patients.
Critical point: no single universal "pollen shot" exists. SCIT formulation is patient-specific based on IgE testing results. A patient sensitized to timothy grass and short ragweed receives a different formulation than one sensitized to birch and mountain cedar. The allergist reviews all sensitizations and selects the clinically relevant ones for the vial.
Pediatric data: Jacobsen L et al. (Allergy 2007, PAT 10-year follow-up) showed a 3-year pediatric pollen SCIT course roughly halved new-onset asthma at 10-year follow-up. Möller C et al. (JACI 2002, PAT index publication) is the original report.
Curex's at-home SCIT program at $129/month matches the personalized serum to the patient's specific pollen sensitization profile — the same formulation logic as clinic SCIT. Eligible patients self-administer one weekly shot at home, with a serum sterile-compounded to USP <797> standards, a prescribed epinephrine auto-injector confirmed on hand, and first-dose plus dose-escalation Zoom supervision by the prescribing physician. No 24-28 weekly clinic visits required.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Efficacy by allergen — what the data shows
Pollen SCIT efficacy is the best-documented allergen category in the Cochrane database. The following RCT data represent the strongest evidence anchor by allergen type.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youFrequently asked questions
What is the best shot for pollen allergy?
The evidence-based shot for pollen allergy is subcutaneous immunotherapy (SCIT) with a patient-specific allergen extract formulated by a board-certified allergist after allergy testing confirms the specific pollen sensitizations. "Best" depends on which pollens are driving symptoms — the formulation must match the patient's individual IgE sensitization profile. FDA-standardized pollen extracts (short ragweed, timothy, Kentucky bluegrass, perennial rye, sweet vernal, redtop, Bermuda grass) have the most defined potency. Grass and ragweed SCIT have the largest randomized controlled trial evidence bases: Cochrane Calderón 2007 (51 RCTs, SMD −0.73 for seasonal AR) and Creticos 1996 NEJM (ragweed, ~85% symptom reduction). A single "pollen shot" for all pollen types does not exist — the extract is patient-specific.
How long does it take for pollen allergy shots to work?
Most patients with pollen allergies begin to notice improvement within 3-6 months of starting allergy shots — sometimes during the build-up phase itself as the dose approaches maintenance level. Full therapeutic benefit — the maximum symptom reduction — typically occurs around 12-18 months of consistent treatment. For seasonal pollen allergies, patients often notice the first meaningful improvement during the first pollen season after beginning SCIT (if they started outside the pollen season). The Cochrane Calderón 2007 meta-analysis documented the overall SMD across trials; individual clinical improvement timelines vary. Some patients with grass or ragweed allergy report substantially reduced medication need by their second pollen season on SCIT.
Are there shots for all types of pollen allergies?
Most pollen sensitivities can be treated with SCIT, but evidence quality varies by pollen type. FDA-standardized pollen extracts exist for grass pollens (timothy, Kentucky bluegrass, perennial rye, redtop, sweet vernal, Bermuda) and short ragweed — these have the most reliable potency and strongest RCT bases. Tree pollen extracts (birch, oak, maple, cedar, elm) are non-standardized, meaning potency varies by manufacturer; birch SCIT is well-studied in European trials (Bødtger U et al., Allergy 2002), and SCIT is practiced for these despite non-standardization. Mountain cedar is an important exception — SCIT efficacy for mountain cedar specifically is not well-studied in RCTs, and some allergists are more conservative about including it. Weed pollens beyond ragweed (mugwort, plantain, English plantain) are also non-standardized but commonly included in multi-allergen formulations.
Is there a one-shot cure for pollen allergy?
No — there is no single one-shot cure for pollen allergy. SCIT requires a 3-to-5-year multi-injection course to achieve durable immune tolerance. The build-up phase alone involves 24-28 weekly injections before the maintenance dose is reached (Cox 2011 PP3). The durability evidence from Durham SR et al. (NEJM 1999;341:468-475) was specifically from patients who completed the full 3-4 year course — not from a single or few injections. A single depot corticosteroid injection (Kenalog, Depo-Medrol) can suppress pollen allergy symptoms for a season but produces no immune modification and carries systemic steroid risks. Cox 2011 PP3 explicitly discourages depot corticosteroids for routine allergic rhinitis management.
Can children get allergy shots for pollen allergies?
Yes — children aged 5 and older are endorsed for SCIT per Cox L et al. (J Allergy Clin Immunol 2011;127[1 Suppl]:S1-S55). Pediatric pollen SCIT has both efficacy and long-term preventive benefits. The PAT (Preventive Allergy Treatment) study (Möller C et al., JACI 2002; Jacobsen L et al., Allergy 2007) found that children who completed a 3-year grass/birch SCIT course had approximately half the rate of new-onset asthma at 10-year follow-up compared to control children. This asthma-prevention benefit — in addition to symptom control — is a compelling reason to consider early SCIT in symptomatic children. Children under 5 are generally not enrolled due to the practical challenges of the observation period and the limited ability to communicate reactions, though individual allergist protocols may vary for highly motivated families.
Do pollen allergy shots help with asthma?
Yes — pollen SCIT has documented benefits for allergic asthma driven by pollen sensitization. Abramson MJ et al. (Cochrane 2010;CD001186, DOI 10.1002/14651858.CD001186.pub2) analyzed 88 SCIT trials across allergen types and found an NNT of 3 to prevent one patient's asthma deterioration. The PAT study specifically documented that pediatric grass/birch pollen SCIT roughly halved new asthma onset at 10-year follow-up. For adults with pollen-driven asthma, SCIT is indicated when asthma is mild-to-moderate and controlled at baseline (Cox 2011 PP3). Uncontrolled asthma (FEV1 <70% predicted) is a contraindication to SCIT initiation — not a contraindication to consideration after asthma control is achieved. Inhaled corticosteroids and short-acting bronchodilators remain the primary asthma pharmacotherapy during the SCIT course.
What happens to pollen allergy after stopping shots?
For most grass and ragweed pollen patients who complete a full 3-5 year SCIT course, the benefit persists for years after stopping. Durham SR et al. (NEJM 1999;341:468-475) demonstrated sustained clinical remission for at least 3 years post-discontinuation in grass SCIT patients. Long-term observational data suggest continued benefit 7-12+ years out for some patients. Relapse rates vary by allergen: grass pollen has among the lowest relapse rates (supported by the Durham 1999 data), while dust mite patients have reported relapse in up to 55% within 5 years of stopping (Cox L, Cohn JR, Ann Allergy Asthma Immunol 2007). Patients who relapse can be re-evaluated and re-initiated on a new SCIT course or sublingual immunotherapy. The stop/continue decision at 5 years is individualized with the prescribing allergist.
Related Articles
Allergy Injections Guide: Schedule & Safety | Curex
Allergy injections (SCIT) mean 60-80+ visits over 3-5 years. Cochrane 51 RCTs: SMD -0.73. Learn what goes in the vial, the schedule, and real-world adherence data.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shots for Hives: SCIT vs Xolair | Curex Guide
Allergy shots (SCIT) not first-line for chronic hives — Xolair is (FDA 2014). Exception: venom shots (VIT) for Hymenoptera-triggered hives. Full guide.
Read moreAllergy Shots Treatment: Evidence & Schedule | Curex
Allergy shots treatment is 3-5 yr SCIT: Cochrane SMD −0.73, NNT 3 for asthma, 1 fatality per 2.5M injections. Not for chronic urticaria or food allergy. Full guide.
Read moreSeasonal Allergy Shots Schedule & Count | Curex Guide
Seasonal allergy shots total 60–80 injections over 3–5 years. Cox 2011: 39 Year-1 visits. Learn the schedule mechanics and why adherence drops after visit one.
Read moreAllergy Shot Test: Skin Testing vs SCIT | Curex Guide
Allergy shot test = skin prick testing (CPT 95004, diagnostic). NOT the same as a SCIT shot (CPT 95117). HOPD test panels billed $24,400–$48,329.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.